The Inducible Secreting TLR5 Agonist, CBLB502, Enhances the Anti-tumor Activity of CAR133-NK92 Cells in Colorectal Cancer

Investigators engineered CAR133-i502-NK92 cells and demonstrated that those cells displayed enhanced proliferation and specific anti-tumor activities in vitro and in a xenogeneic mouse model, and were well-tolerated.